Agenus Stock Scheduled to Reverse Split on Friday, April 12th (NASDAQ:AGEN)

Shares of Agenus Inc. (NASDAQ:AGEN) are set to reverse split before the market opens on Friday, April 12th. The 1-20 reverse split was announced on Friday, April 12th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, April 12th.

Agenus Trading Down 7.6 %

Agenus stock traded down $0.04 during trading hours on Monday, reaching $0.47. 26,355,944 shares of the company were exchanged, compared to its average volume of 10,497,963. The firm has a market cap of $195.01 million, a price-to-earnings ratio of -0.66 and a beta of 1.26. The stock has a 50-day moving average of $0.64 and a 200 day moving average of $0.76. Agenus has a 12 month low of $0.41 and a 12 month high of $2.13.

Agenus (NASDAQ:AGEN) last announced its earnings results on Thursday, March 14th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.11). The business had revenue of $83.80 million during the quarter, compared to analysts’ expectations of $54.21 million. As a group, research analysts forecast that Agenus will post -0.41 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on AGEN shares. StockNews.com raised Agenus from a “sell” rating to a “hold” rating in a research report on Sunday, March 24th. HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of Agenus in a research report on Thursday, March 14th. Finally, B. Riley reduced their price objective on Agenus from $6.00 to $5.00 and set a “buy” rating for the company in a research report on Monday, March 18th.

Insiders Place Their Bets

In other Agenus news, insider Garo H. Armen bought 500,000 shares of the firm’s stock in a transaction dated Thursday, February 15th. The shares were acquired at an average cost of $0.65 per share, for a total transaction of $325,000.00. Following the transaction, the insider now owns 625,969 shares in the company, valued at $406,879.85. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 4.80% of the company’s stock.

Institutional Trading of Agenus

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. U.S. Capital Wealth Advisors LLC bought a new stake in Agenus during the first quarter worth about $25,000. Commonwealth Equity Services LLC bought a new stake in Agenus during the third quarter worth about $26,000. Sei Investments Co. bought a new stake in Agenus during the first quarter worth about $28,000. SG Americas Securities LLC bought a new stake in Agenus during the third quarter worth about $36,000. Finally, Two Sigma Securities LLC grew its stake in Agenus by 116.9% during the second quarter. Two Sigma Securities LLC now owns 22,750 shares of the biotechnology company’s stock worth $36,000 after buying an additional 12,263 shares during the last quarter. Institutional investors own 61.46% of the company’s stock.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.